Search

Your search keyword '"Bonifacio M"' showing total 494 results
Start Over Author "Bonifacio M"
494 results on '"Bonifacio M"'

55. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study

Author

De Stefano, V., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Rossi, E., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Rapezzi, D., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., McMullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Marchetti, M., Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Rambaldi, A., Barbui, T., De Stefano V. (ORCID:0000-0002-5178-5827), Rossi E. (ORCID:0000-0002-7572-9379), De Stefano, V., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Rossi, E., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Rapezzi, D., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., McMullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Marchetti, M., Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Rambaldi, A., Barbui, T., De Stefano V. (ORCID:0000-0002-5178-5827), and Rossi E. (ORCID:0000-0002-7572-9379)

Abstract

Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second cancers, but the factors associated with these events have been poorly explored. In an international nested case-control study, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or after MPN diagnosis. Up to 3 control patients without a history of cancer and matched with each case for center, sex, age at MPN diagnosis, date of diagnosis, and MPN disease duration were included (n 5 1234). Cases were comparable to controls for MPN type, driver mutations and cardiovascular risk factors. The frequency of thrombosis preceding MPN was similar for cases and controls (P 5 .462). Thrombotic events after MPN and before second cancer were higher in cases than in controls (11.6% vs 8.1%; P 5 .013), because of a higher proportion of arterial thromboses (6.2% vs 3.7%; P 5 .015). After adjustment for confounders, the occurrence of arterial thrombosis remained independently associated with the risk of carcinoma (odds ratio, 1.97; 95% confidence interval, 1.14-3.41), suggesting that MPN patients experiencing arterial events after MPN diagnosis deserve careful clinical surveillance for early detection of carcinoma.

Published
2020

56. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

Author

Barbui, T., Ghirardi, A., Vannucchi, A. M., Marchetti, M., De Stefano, Valerio, Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Griesshammer, M., Alvarez-Larran, A., Rambaldi, A., De Stefano V. (ORCID:0000-0002-5178-5827), Barbui, T., Ghirardi, A., Vannucchi, A. M., Marchetti, M., De Stefano, Valerio, Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Griesshammer, M., Alvarez-Larran, A., Rambaldi, A., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2020

57. Second cancers in MPN: Survival analysis from an international study

Author

Marchetti, M., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Rossi, Elena, Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Rapezzi, D., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Pane, F., De Stefano, Valerio, Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Rambaldi, A., Barbui, T., Rossi E. (ORCID:0000-0002-7572-9379), De Stefano V. (ORCID:0000-0002-5178-5827), Marchetti, M., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Rossi, Elena, Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Rapezzi, D., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Pane, F., De Stefano, Valerio, Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Rambaldi, A., Barbui, T., Rossi E. (ORCID:0000-0002-7572-9379), and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

One out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 patients with SC diagnosed concurrently or after the MPN. Overall, 2995 person-years (PYs) were accumulated and mortality rate (MR) since SC diagnosis was 5.9 (5.1-6.9) deaths for every 100 PYs. A “poor prognosis” SC (stomach, esophagus, liver, pancreas, lung, ovary, head-and-neck or nervous system, osteosarcomas, multiple myeloma, aggressive lymphoma, acute leukemia) was reported in 26.3% of the patients and was the cause of death in 65% of them (MR 11.0/100 PYs). In contrast, patients with a “non-poor prognosis” SC (NPPSC) incurred a MR of 4.6/100 PYs: 31% of the deaths were attributed to SC and 15% to MPN evolution. At multivariable analysis, death after SC diagnosis was independently predicted (HR and 95% CI) by patient age greater than 70 years (2.68; 1.88-3.81), the SC prognostic group (2.57; 1.86-3.55), SC relapse (1.53; 10.6-2.21), MPN evolution (2.72; 1.84-4.02), anemia at SC diagnosis (2.32; 1.49-3.59), exposure to hydroxyurea (1.89; 1.26-2.85) and to ruxolitinib (3.63; 1.97-6.71). Aspirin was protective for patients with a NPPSC (0.60; 0.38-0.95). In conclusion, SC is a relevant cause of death competing with MPN evolution. Prospective data are awaited to confirm the role of cytoreductive and anti-platelet drugs in modulating patient survival after the occurrence of a SC.

Published
2020

58. Mapping density, diversity and species-richness of the Amazon tree flora

Author

Hans ter Steege, Nigel C. A. Pitman, Iêda Leão do Amaral, Luiz de Souza Coelho, Francisca Dionízia de Almeida Matos, Diógenes de Andrade Lima Filho, Rafael P. Salomão, Florian Wittmann, Carolina V. Castilho, Juan Ernesto Guevara, Marcelo de Jesus Veiga Carim, Oliver L. Phillips, William E. Magnusson, Daniel Sabatier, Juan David Cardenas Revilla, Jean-François Molino, Mariana Victória Irume, Maria Pires Martins, José Renan da Silva Guimarães, José Ferreira Ramos, Olaf S. Bánki, Maria Teresa Fernandez Piedade, Dairon Cárdenas López, Domingos de Jesus Rodrigues, Layon O. Demarchi, Jochen Schöngart, Everton José Almeida, Luciane Ferreira Barbosa, Larissa Cavalheiro, Márcia Cléia Vilela dos Santos, Bruno Garcia Luize, Evlyn Márcia Moraes de Leão Novo, Percy Núñez Vargas, Thiago Sanna Freire Silva, Eduardo Martins Venticinque, Angelo Gilberto Manzatto, Neidiane Farias Costa Reis, John Terborgh, Katia Regina Casula, Euridice N. Honorio Coronado, Abel Monteagudo Mendoza, Juan Carlos Montero, Flávia R. C. Costa, Ted R. Feldpausch, Adriano Costa Quaresma, Nicolás Castaño Arboleda, Charles Eugene Zartman, Timothy J. Killeen, Beatriz S. Marimon, Ben Hur Marimon-Junior, Rodolfo Vasquez, Bonifacio Mostacedo, Rafael L. Assis, Chris Baraloto, Dário Dantas do Amaral, Julien Engel, Pascal Petronelli, Hernán Castellanos, Marcelo Brilhante de Medeiros, Marcelo Fragomeni Simon, Ana Andrade, José Luís Camargo, William F. Laurance, Susan G. W. Laurance, Lorena Maniguaje Rincón, Juliana Schietti, Thaiane R. Sousa, Emanuelle de Sousa Farias, Maria Aparecida Lopes, José Leonardo Lima Magalhães, Henrique Eduardo Mendonça Nascimento, Helder Lima de Queiroz, Gerardo A. Aymard C., Roel Brienen, Pablo R. Stevenson, Alejandro Araujo-Murakami, Tim R. Baker, Bruno Barçante Ladvocat Cintra, Yuri Oliveira Feitosa, Hugo F. Mogollón, Joost F. Duivenvoorden, Carlos A. Peres, Miles R. Silman, Leandro Valle Ferreira, José Rafael Lozada, James A. Comiskey, Freddie C. Draper, José Julio de Toledo, Gabriel Damasco, Roosevelt García-Villacorta, Aline Lopes, Alberto Vicentini, Fernando Cornejo Valverde, Alfonso Alonso, Luzmila Arroyo, Francisco Dallmeier, Vitor H. F. Gomes, Eliana M. Jimenez, David Neill, Maria Cristina Peñuela Mora, Janaína Costa Noronha, Daniel P. P. de Aguiar, Flávia Rodrigues Barbosa, Yennie K. Bredin, Rainiellen de Sá Carpanedo, Fernanda Antunes Carvalho, Fernanda Coelho de Souza, Kenneth J. Feeley, Rogerio Gribel, Torbjørn Haugaasen, Joseph E. Hawes, Marcelo Petratti Pansonato, Marcos Ríos Paredes, Jos Barlow, Erika Berenguer, Izaias Brasil da Silva, Maria Julia Ferreira, Joice Ferreira, Paul V. A. Fine, Marcelino Carneiro Guedes, Carolina Levis, Juan Carlos Licona, Boris Eduardo Villa Zegarra, Vincent Antoine Vos, Carlos Cerón, Flávia Machado Durgante, Émile Fonty, Terry W. Henkel, John Ethan Householder, Isau Huamantupa-Chuquimaco, Edwin Pos, Marcos Silveira, Juliana Stropp, Raquel Thomas, Doug Daly, Kyle G. Dexter, William Milliken, Guido Pardo Molina, Toby Pennington, Ima Célia Guimarães Vieira, Bianca Weiss Albuquerque, Wegliane Campelo, Alfredo Fuentes, Bente Klitgaard, José Luis Marcelo Pena, J. Sebastián Tello, Corine Vriesendorp, Jerome Chave, Anthony Di Fiore, Renato Richard Hilário, Luciana de Oliveira Pereira, Juan Fernando Phillips, Gonzalo Rivas-Torres, Tinde R. van Andel, Patricio von Hildebrand, William Balee, Edelcilio Marques Barbosa, Luiz Carlos de Matos Bonates, Hilda Paulette Dávila Doza, Ricardo Zárate Gómez, Therany Gonzales, George Pepe Gallardo Gonzales, Bruce Hoffman, André Braga Junqueira, Yadvinder Malhi, Ires Paula de Andrade Miranda, Linder Felipe Mozombite Pinto, Adriana Prieto, Agustín Rudas, Ademir R. Ruschel, Natalino Silva, César I. A. Vela, Egleé L. Zent, Stanford Zent, Angela Cano, Yrma Andreina Carrero Márquez, Diego F. Correa, Janaina Barbosa Pedrosa Costa, Bernardo Monteiro Flores, David Galbraith, Milena Holmgren, Michelle Kalamandeen, Guilherme Lobo, Luis Torres Montenegro, Marcelo Trindade Nascimento, Alexandre A. Oliveira, Maihyra Marina Pombo, Hirma Ramirez-Angulo, Maira Rocha, Veridiana Vizoni Scudeller, Rodrigo Sierra, Milton Tirado, Maria Natalia Umaña, Geertje van der Heijden, Emilio Vilanova Torre, Manuel Augusto Ahuite Reategui, Cláudia Baider, Henrik Balslev, Sasha Cárdenas, Luisa Fernanda Casas, María José Endara, William Farfan-Rios, Cid Ferreira, Reynaldo Linares-Palomino, Casimiro Mendoza, Italo Mesones, Germaine Alexander Parada, Armando Torres-Lezama, Ligia Estela Urrego Giraldo, Daniel Villarroel, Roderick Zagt, Miguel N. Alexiades, Edmar Almeida de Oliveira, Karina Garcia-Cabrera, Lionel Hernandez, Walter Palacios Cuenca, Susamar Pansini, Daniela Pauletto, Freddy Ramirez Arevalo, Adeilza Felipe Sampaio, Elvis H. Valderrama Sandoval, Luis Valenzuela Gamarra, Aurora Levesley, Georgia Pickavance, and Karina Melgaço

Subjects
Biology (General), QH301-705.5
Abstract

Abstract Using 2.046 botanically-inventoried tree plots across the largest tropical forest on Earth, we mapped tree species-diversity and tree species-richness at 0.1-degree resolution, and investigated drivers for diversity and richness. Using only location, stratified by forest type, as predictor, our spatial model, to the best of our knowledge, provides the most accurate map of tree diversity in Amazonia to date, explaining approximately 70% of the tree diversity and species-richness. Large soil-forest combinations determine a significant percentage of the variation in tree species-richness and tree alpha-diversity in Amazonian forest-plots. We suggest that the size and fragmentation of these systems drive their large-scale diversity patterns and hence local diversity. A model not using location but cumulative water deficit, tree density, and temperature seasonality explains 47% of the tree species-richness in the terra-firme forest in Amazonia. Over large areas across Amazonia, residuals of this relationship are small and poorly spatially structured, suggesting that much of the residual variation may be local. The Guyana Shield area has consistently negative residuals, showing that this area has lower tree species-richness than expected by our models. We provide extensive plot meta-data, including tree density, tree alpha-diversity and tree species-richness results and gridded maps at 0.1-degree resolution.

Published
2023
Full Text
View/download PDF

59. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

Author

Barbui, T., Ghirardi, A., Vannucchi, A. M., Marchetti, M., De Stefano, Valerio, Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Griesshammer, M., Alvarez-Larran, A., and Rambaldi, A.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Aspirin, business.industry, Hematology, Second primary cancer, Settore MED/15 - MALATTIE DEL SANGUE, Internal medicine, medicine, business, Myelopriferative neoplasms, medicine.drug
Published
2019
Full Text
View/download PDF

60. PF174 GERIATRIC ASSESSMENT-BASED TREATMENT OF ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. RESULTS OF THE GIMEMA LAL1104 PROTOCOL

Author

Chiaretti, S., primary, Cesini, L., additional, Di Raimondo, F., additional, Angelucci, E., additional, Luppi, M., additional, Bonifacio, M., additional, Cascavilla, N., additional, Fozza, C., additional, La Sala, E., additional, Soddu, S., additional, Fazi, P., additional, Vitale, A., additional, Foà, R., additional, and Ferrara, F., additional

Published
2019
Full Text
View/download PDF

61. PF674 OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS

Author

Palandri, F., primary, Breccia, M., additional, Bonifacio, M., additional, Polverelli, N., additional, Elli, E.M., additional, Benevolo, G., additional, Tiribelli, M., additional, Abruzzese, E., additional, Iurlo, A., additional, Heidel, F., additional, Bergamaschi, M., additional, Tieghi, A., additional, Crugnola, M., additional, Cavazzini, F., additional, Binotto, G., additional, Isidori, A., additional, Sgherza, N., additional, Bosi, C., additional, Martino, B., additional, Latagliata, R., additional, Auteri, G., additional, Scaffidi, L., additional, Griguolo, D., additional, Trawinska, M., additional, Cattaneo, D., additional, Catani, L., additional, Krampera, M., additional, Vitolo, U., additional, Lemoli, R.M., additional, Cuneo, A., additional, Semenzato, G., additional, Foà, R., additional, Raimondo, F. Di, additional, Bartoletti, D., additional, Cavo, M., additional, Palumbo, G.A., additional, and Vianelli, N., additional

Published
2019
Full Text
View/download PDF

62. S1619 BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH BCELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCPALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS

Author

Goekbuget, N., primary, Dombret, H., additional, Zugmaier, G., additional, Bonifacio, M., additional, Graux, C., additional, Faul, C., additional, Topp, M.S., additional, Brüggemann, M., additional, Taylor, K., additional, and Bargou, R., additional

Published
2019
Full Text
View/download PDF

63. S123 SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED

Author

Mancini, M., primary, De Santis, S., additional, Monaldi, C., additional, Bavaro, L., additional, Martelli, M., additional, Castagnetti, F., additional, Gugliotta, G., additional, Rosti, G., additional, Fontana, M.C., additional, Dan, E., additional, Sinigallia, B., additional, Iurlo, A., additional, Orofino, N., additional, Abbruzzese, E., additional, Salvucci, M., additional, Pregno, P., additional, Gozzini, A., additional, Crugnola, M., additional, Albano, F., additional, Bonifacio, M., additional, Calistri, E., additional, Tiribelli, M., additional, Binotto, G., additional, Imovilli, A., additional, Trabacchi, E., additional, Galimberti, S., additional, Baratè, C., additional, Tenti, E., additional, Baccarani, M., additional, Martinelli, G., additional, Cavo, M., additional, and Soverini, S., additional

Published
2019
Full Text
View/download PDF

64. S1617 A DASATINIB-BLINATUMOMAB COMBINATION FOR THE FRONT-LINE TREATMENT OF ADULT PH+ ALL PATIENTS. PRELIMINARY RESULTS OF THE GIMEMA LAL2116 D-ALBA TRIAL; ON BEHALF OF GIMEMA ACUTE LEUKEMIA WORKING PARTY

Author

Chiaretti, S., primary, Bassan, R., additional, Vitale, A., additional, Elia, L., additional, Piciocchi, A., additional, Ferrara, F., additional, Lunghi, M., additional, Fabbiano, F., additional, Bonifacio, M., additional, Fracchiolla, N., additional, Salutari, P., additional, Mancino, A., additional, Vignetti, M., additional, Rambaldi, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

65. S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

Author

Malagola, M., primary, Efficace, F., additional, Polverelli, N., additional, Cottone, F., additional, Abruzzese, E., additional, Iurlo, A., additional, Bucelli, C., additional, Stagno, F., additional, Bonifacio, M., additional, D’Adda, M., additional, Lunghi, M., additional, Crugnola, M., additional, Lunghi, F., additional, Castagnetti, F., additional, Rosti, G., additional, Ferrari, M.L., additional, Bergamaschi, M., additional, Binotto, G., additional, Sancetta, R., additional, Coppi, M.R., additional, Giai, V., additional, Rege Cambrin, G., additional, Romano, A., additional, Tiribelli, M., additional, Russo, S., additional, Aprile, L., additional, Falcone, A.P., additional, Rupoli, S., additional, Russo Rossi, A., additional, Usala, E., additional, Martino, B., additional, Gandolfi, L., additional, Bernardi, S., additional, Zanaglio, C., additional, Farina, M., additional, Baccarani, M., additional, and Russo, D., additional

Published
2019
Full Text
View/download PDF

66. S1620 NELARABINE AS SALVAGE THERAPY AND BRIDGE TO ALLOGENEIC STEM CELLS TRANSPLANTATION IN 118 ADULT PATIENTS WITH RELAPSED/REFRACTORY T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA. A CAMPUS-ALL, PHASE 4, STUDY.

Author

Candoni, A., primary, Lazzarotto, D., additional, Curti, A., additional, Ferrara, F., additional, Lussana, F., additional, Papayannidis, C., additional, Del Principe, M.I., additional, Bonifacio, M., additional, Mosna, F., additional, Delia, M., additional, Minetto, P., additional, Gottardi, M., additional, Fracchiolla, N., additional, Mancini, V., additional, Forghieri, F., additional, Zappasoldi, P., additional, Cerrano, M., additional, Vitale, A., additional, Audisio, E., additional, Trappolini, S., additional, Romani, C., additional, Defina, M., additional, Imbergamo, S., additional, Ciccone, N., additional, Santoro, L., additional, Cambò, B., additional, Iaccarino, S., additional, Dargenio, M., additional, Aprile, L., additional, Pizzolo, G., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

67. PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS

Author

Barbui, T., primary, Ghirardi, A., additional, Masciulli, A., additional, Carobbio, A., additional, Palandri, F., additional, Vianelli, N., additional, De Stefano, V., additional, Betti, S., additional, Di Veroli, A., additional, Iurlo, A., additional, Cattaneo, D., additional, Delaini, F., additional, Bonifacio, M., additional, Scaffidi, L., additional, Patriarca, A., additional, Rumi, E., additional, Stephenson, C., additional, Guglielmelli, P., additional, Elli, E.M., additional, Miroslava, P., additional, Bertolotti, L., additional, Erez, D., additional, Gomez, M., additional, Wille, K., additional, Perez-Encinas, M., additional, Lunghi, F., additional, Angona, A., additional, Fox, M.L., additional, Beggiato, E., additional, Benevolo, G., additional, Carli, G., additional, Cacciola, R., additional, McMullin, M.F., additional, Tieghi, A., additional, Recasens, V., additional, Marchetti, M., additional, Griesshammer, M., additional, Alvarez-Larran, A., additional, Vannucchi, A., additional, and Finazzi, G., additional

Published
2019
Full Text
View/download PDF

68. PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Author

Soverini, S., primary, Martelli, M., additional, Bavaro, L., additional, Papayannidis, C., additional, Sica, S., additional, Sorà, F., additional, Albano, F., additional, Galimberti, S., additional, Barate’, C., additional, Rondoni, M., additional, Abruzzese, E., additional, Annunziata, M., additional, Russo, S., additional, Mannina, D., additional, Stulle, M., additional, Imovilli, A., additional, Curti, A., additional, Bonifacio, M., additional, Ferrero, D., additional, Basilico, C., additional, Reddiconto, G., additional, Mineo, G., additional, Laginestra, M.A., additional, Pileri, S.A., additional, Mignone, F., additional, Percesepe, A., additional, Martinelli, G., additional, and Cavo, M., additional

Published
2019
Full Text
View/download PDF

69. PB1930 CORRELATION BETWEEN LEVELS OF EARLY MOLECULAR RESPONSE AND BCR-ABL TRANSCRIPT TYPE IN STABLE DMR ATTAINMENT IN CML PATIENTS TREATED WITH IMATINIB

Author

Tiribelli, M., primary, Bonifacio, M., additional, Binotto, G., additional, Griguolo, D., additional, Scaffidi, L., additional, Frison, L., additional, Miggiano, M.C., additional, Calistri, E., additional, Stulle, M., additional, De Biasi, E., additional, Sartori, R., additional, Stella, R., additional, Tanasi, I., additional, Ruggeri, M., additional, Damiani, D., additional, Semenzato, G., additional, Krampera, M., additional, and Fanin, R., additional

Published
2019
Full Text
View/download PDF

70. PS1461 FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES

Author

Tanasi, I., primary, Bonifacio, M., additional, Pizzolato, M., additional, Grifoni, F.I., additional, Sciumè, M., additional, Elena, C., additional, Benvenuti, P., additional, Mannelli, F., additional, Parente, R., additional, Schena, D., additional, Scaffidi, L., additional, Bonadonna, P., additional, Papayannidis, C., additional, Rondoni, M., additional, Criscuolo, M., additional, Vannucchi, A.M., additional, Triggiani, M., additional, Martinelli, G., additional, Krampera, M., additional, and Zanotti, R., additional

Published
2019
Full Text
View/download PDF

71. outcome of very elderly chronic myeloid leukemia patients treated with imatinib frontline

Author

Crugnola, M, Castagnetti, F, Breccia, M, Ferrero, D, Trawinska, Mm, Abruzzese, E, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Bonifacio, M, Fava, C, Iurlo, A, Bucelli, C, Mansueto, G, Gozzini, A, Falzetti, F, Montefusco, E, Crisà, E, Gugliotta, G, Russo, S, Cedrone, M, Russorossi, A, Pregno, P, Isidori, A, Mauro, E, Atelda, R, Giglio, G, Celesti, F, Sora', Federica, Storti, S, D'Addosio, A, Galimberti, S, Orlandi, E, Calistri, E, Bocchia, M, Cavazzini, F, Cambrin, Gr, Orofino, N, Luciano, L, Sgherza, N, Rosti, G, Latagliata, R, Capodanno, I, Sora, Federica (ORCID:0000-0002-9607-5298), Crugnola, M, Castagnetti, F, Breccia, M, Ferrero, D, Trawinska, Mm, Abruzzese, E, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Bonifacio, M, Fava, C, Iurlo, A, Bucelli, C, Mansueto, G, Gozzini, A, Falzetti, F, Montefusco, E, Crisà, E, Gugliotta, G, Russo, S, Cedrone, M, Russorossi, A, Pregno, P, Isidori, A, Mauro, E, Atelda, R, Giglio, G, Celesti, F, Sora', Federica, Storti, S, D'Addosio, A, Galimberti, S, Orlandi, E, Calistri, E, Bocchia, M, Cavazzini, F, Cambrin, Gr, Orofino, N, Luciano, L, Sgherza, N, Rosti, G, Latagliata, R, Capodanno, I, and Sora, Federica (ORCID:0000-0002-9607-5298)

Abstract

Very elderly (> 75 years) chronic myeloid leukaemia (CML) patients at diagnosis are sometimes treated with different doses of imatinib (IM) based on concomitant diseases and physicians' judgement. However, data on long-term follow-up of these patients are still lacking. To investigate treatment response and outcome, we retrospectively revised an Italian database of 263 very elderly CML patients receiving IM from the time of diagnosis. Median age at diagnosis was 78.5 years and 56% of patients had 2 or 3 comorbidities. A complete haematological and cytogenetic response were achieved in 244 (92.8%) and 184 (69.9%) patients, respectively. In 148 cases (56.2%), a major molecular response was observed, which was deep in 63 cases (24%). A blastic phase occurred in 11 patients (4.2%). After a median follow-up of 45.0 months, 93 patients have died (9 from disease progression) and 104 (39.5%) are still in treatment with IM. Incidence of grades 3-4 haematological and non-haematological toxicity was similar to those reported in younger patients. Five-year event-free survival was 54.5% and 45.2% in patients ≤ 80 years and > 80 years, respectively (p = 0.098). Five years OS was 75.7% and 61.6% in patients ≤80 years and > 80 years, respectively (p = 0.003). These findings show that IM plays an important role in frontline treatment of very elderly CML patients without increased toxicity and any effort to treat these patients with standard doses should be made in order to achieve responses as in younger subjects

Published
2019

72. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

Author

M., Baccarani, F., Castagnetti, G., Gugliotta, G., Rosti, S., Soverini, A., Albeer, M., Pfirrmann, Bekadja, Entasoltan, M-A, Nachi, B, Elghandour, M, El Sorady, A, Abdelfattah, M, El Nahass, R, Samra, Y, Azzazi, M, Elsobki, M, Moussa, E, Fahmy, M, Mattar, O, Shehata, M, Azmy, Se, Bolarinwa, E, Eid, Ra, Khelif, S, Hached, A, Menif, F, Rahman, S, Huang, H, Jiang, X, Ye, Q, Zhu, Y, Chen, H, Varma, S, Ganesan, N, Gundeti, P, Malhotra, S, Radhakrishnan, H, Kumar, V, Sharawat, L, Seth, Sk, Ausekar, T, Balasubramanian, Bv, Poopak, P, Inokuchi, B, Kim, K, Al Kindi, D-W, Mirasol, S, Qari, A, Goh, M, Shih, Yt, Branford, L-Y, Lion, S, Valent, T, Burgstaller, P, Thaler, S, Labar, J, Zadro, B, Mayer, R, Zackova, J, Faber, D, Pallisgaard, E, Xavier-Mahon, N, Lippert, F, Cayuela, E, Rea, Jm, Millot, D, Suttorp, F, Hochhaus, M, Niederwieser, A, Saussele, D, Haferlach, S, Jeromine, T, Panayiotidis, S, Conneally, P, Langabeer, E, Nagler, S, Rupoli, A, Santoro, S, Albano, N, Castagnetti, F, Ottaviani, F, Rambaldi, E, Stagno, A, Molica, F, Biagiotti, S, Scappini, C, Lemoli, B, Iurlo, R, Pungolino, A, Menna, E, Pane, G, Gottardi, F, Rege-Cambrin, E, Binotto, G, Putti, G, Falzetti, Mc, Visani, F, Galimberti, G, Musto, S, Abruzzese, P, Breccia, E, Giona, M, F, Chiusolo, Patrizia, Sica, Simona, Fava, Ferrero, C, Tiribelli, D, Bonifacio, M, Griskevicius, M, Musteata, L, Janssen, V, Prejzner, J, Sacha, W, Waclaw, T, Almeida, J, Kulikov, Am, Turkina, S, Bogdanovic, A, Zupan, A, Marce, I, Cervantes, S, Steegmann, F, Kotlyarchuk, Jl, Milner, K, Rose, Bj, Clench, S, Waits, T, Austin, P, Wickham, S, Clark, C, Apperley, R, Claudiani, J, Foroni, S, Szydlo, L, Burt, R, Bescoby, E, Cork, R, O'Brien, L, Green, S, Hawtree, B, Watson, S, Bengio, M, Larripa, Rm, Pavlovsky, I, Moiraghi, C, Requiao de Pinna, B, Romani Magalhaes, Ca, Pagnano, Gh, Funke, K, Tavares, V, Prado, R, Azevedo, A, Fogliatto, Aa, Bonecker, L, Centrone, S, Moellman, R, Conchon, A, Centurion, M, Prado, Me, Lopez, A-I, Petruzziello, Jl, Bendit, F, I, Patrizia, Chiusolo (ORCID:0000-0002-1355-1587), S. , Sica (ORCID:0000-0003-2426-3465), M., Baccarani, F., Castagnetti, G., Gugliotta, G., Rosti, S., Soverini, A., Albeer, M., Pfirrmann, Bekadja, Entasoltan, M-A, Nachi, B, Elghandour, M, El Sorady, A, Abdelfattah, M, El Nahass, R, Samra, Y, Azzazi, M, Elsobki, M, Moussa, E, Fahmy, M, Mattar, O, Shehata, M, Azmy, Se, Bolarinwa, E, Eid, Ra, Khelif, S, Hached, A, Menif, F, Rahman, S, Huang, H, Jiang, X, Ye, Q, Zhu, Y, Chen, H, Varma, S, Ganesan, N, Gundeti, P, Malhotra, S, Radhakrishnan, H, Kumar, V, Sharawat, L, Seth, Sk, Ausekar, T, Balasubramanian, Bv, Poopak, P, Inokuchi, B, Kim, K, Al Kindi, D-W, Mirasol, S, Qari, A, Goh, M, Shih, Yt, Branford, L-Y, Lion, S, Valent, T, Burgstaller, P, Thaler, S, Labar, J, Zadro, B, Mayer, R, Zackova, J, Faber, D, Pallisgaard, E, Xavier-Mahon, N, Lippert, F, Cayuela, E, Rea, Jm, Millot, D, Suttorp, F, Hochhaus, M, Niederwieser, A, Saussele, D, Haferlach, S, Jeromine, T, Panayiotidis, S, Conneally, P, Langabeer, E, Nagler, S, Rupoli, A, Santoro, S, Albano, N, Castagnetti, F, Ottaviani, F, Rambaldi, E, Stagno, A, Molica, F, Biagiotti, S, Scappini, C, Lemoli, B, Iurlo, R, Pungolino, A, Menna, E, Pane, G, Gottardi, F, Rege-Cambrin, E, Binotto, G, Putti, G, Falzetti, Mc, Visani, F, Galimberti, G, Musto, S, Abruzzese, P, Breccia, E, Giona, M, F, Chiusolo, Patrizia, Sica, Simona, Fava, Ferrero, C, Tiribelli, D, Bonifacio, M, Griskevicius, M, Musteata, L, Janssen, V, Prejzner, J, Sacha, W, Waclaw, T, Almeida, J, Kulikov, Am, Turkina, S, Bogdanovic, A, Zupan, A, Marce, I, Cervantes, S, Steegmann, F, Kotlyarchuk, Jl, Milner, K, Rose, Bj, Clench, S, Waits, T, Austin, P, Wickham, S, Clark, C, Apperley, R, Claudiani, J, Foroni, S, Szydlo, L, Burt, R, Bescoby, E, Cork, R, O'Brien, L, Green, S, Hawtree, B, Watson, S, Bengio, M, Larripa, Rm, Pavlovsky, I, Moiraghi, C, Requiao de Pinna, B, Romani Magalhaes, Ca, Pagnano, Gh, Funke, K, Tavares, V, Prado, R, Azevedo, A, Fogliatto, Aa, Bonecker, L, Centrone, S, Moellman, R, Conchon, A, Centurion, M, Prado, Me, Lopez, A-I, Petruzziello, Jl, Bendit, F, I, Patrizia, Chiusolo (ORCID:0000-0002-1355-1587), and S. , Sica (ORCID:0000-0003-2426-3465)

Abstract

There are different BCR-ABL1 fusion genes that are translated into proteins that are different from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute lymphoblastic leukemia. Their frequency has never been systematically investigated. In a series of 45503 newly diagnosed CML patients reported from 45 countries, it was found that the proportion of e13a2 (also known as b2a2) and of e14a2 (also known as b3a2), including the cases co-expressing e14a2 and e13a2, was 37.9% and 62.1%, respectively. The proportion of these two transcripts was correlated with gender, e13a2 being more frequent in males (39.2%) than in females (36.2%), was correlated with age, decreasing from 39.6% in children and adolescents down to 31.6% in patients ≥ 80 years old, and was not constant worldwide. Other, rare transcripts were reported in 666/34561 patients (1.93%). The proportion of rare transcripts was associated with gender (2.27% in females and 1.69% in males) and with age (from 1.79% in children and adolescents up to 3.84% in patients ≥ 80 years old). These data show that the differences in proportion are not by chance. This is important, as the transcript type is a variable that is suspected to be of prognostic importance for response to treatment, outcome of treatment, and rate of treatment-free remission.

Published
2019

73. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Author

Barbui, T., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., De Stefano, Valerio, Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Delaini, F., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Marchetti, M., Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Finazzi, G., De Stefano V. (ORCID:0000-0002-5178-5827), Barbui, T., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., De Stefano, Valerio, Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Delaini, F., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Marchetti, M., Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Finazzi, G., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

We conducted a large international nested case-control study including 1881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration. The aim was to evaluate the risk of SC after exposure to cytoreductive drugs. Patients exposed to hydroxyurea (HU) (median: 3 years) had a risk of SC similar to unexposed patients (OR = 1.06, 95% CI 0.82–1.38). In contrast, in cancer-specific stratified multivariable analysis, HU had two-fold higher risk of non-melanoma (NM) skin cancer (OR = 2.28, 95% CI 1.15–4.51). A significantly higher risk of NM-skin cancer was also documented for pipobroman (OR = 3.74, 95% CI 1.00–14.01), ruxolitinib (OR = 3.87, 95% CI 1.18–12.75), and for drug combination (OR = 3.47, 95% CI 1.55–7.75). These three drugs did not show excess risk of carcinoma and hematological second cancer compared with unexposed patients. Exposure to interferon, busulfan, and anagrelide did not increase the risk. In summary, while it is reassuring that no excess of carcinoma was documented, a careful dermatologic active surveillance before and during the course of treatments is recommended.

Published
2019

74. Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

Author

Breccia, M., Luciano, L., Pugliese, N., Rossi, Elena, Tiribelli, M., Scalzulli, E., Bonifacio, M., Martino, B., Latagliata, R., Benevolo, G., Caocci, G., Binotto, G., Martinelli, V., Cavo, M., Pane, F., De Stefano, Valerio, Foa, R., Palandri, F., Rossi E. (ORCID:0000-0002-7572-9379), De Stefano V. (ORCID:0000-0002-5178-5827), Breccia, M., Luciano, L., Pugliese, N., Rossi, Elena, Tiribelli, M., Scalzulli, E., Bonifacio, M., Martino, B., Latagliata, R., Benevolo, G., Caocci, G., Binotto, G., Martinelli, V., Cavo, M., Pane, F., De Stefano, Valerio, Foa, R., Palandri, F., Rossi E. (ORCID:0000-0002-7572-9379), and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. During treatment, as rare conditions, leukocytosis and/or thrombocytosis could develop and the management of these situations is not well established. We report here 53 myelofibrosis patients that received a combination of hydroxyurea and ruxolitinib because of uncontrolled myeloproliferation. Both drugs were administered outside clinical trials. At 48 weeks, a significant reduction in leucocyte and platelet counts was observed (p = 0.02 and p = 0.04, respectively). Additionally, the spleen volume decreased from a median value of 10 cm below the left costal margin (range, 0–10) to 6 cm (range, 0–15). The rate of spleen response increased from 14% at the start of the combination to 45% after 48 weeks. The safety profile of the combination was consistent with that observed with ruxolitinib single agent. These data require further confirmation in large cohorts of patients prospectively assessed.

Published
2019

75. Risk factors for secondary cancer in a case-control study on 1,881 patients with myeloproliferative neoplasms (ELN Study)

Author

Barbui, T., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Destefano, V., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Delaini, F., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Stephensom, C., Guglielmelli, P., Elli, E. M., Miroslava, P., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benelovo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Rcasens Flores, V., Marchetti, M., Griesshammer, M., Alvarez-Larran, A., Vannucchi, A., and Finazzi, G.

Published
2018

76. Epilepsia sintomática con inicio que imita el síndrome de Panayiotopoulos: importancia de la neuroimagen

Author

Ignacio Málaga-Diéguez, L. Santoveña-González, Quesada-Colloto P, Raquel Blanco-Lago, Antonio Hedrera-Fernandez, Bonifacio M, and Oreña-Ansorena Va

Subjects
Philosophy, Neurology (clinical), General Medicine, Humanities
Abstract

Introduccion. El sindrome de Panayiotopoulos (SP) es una epilepsia frecuente en la infancia que se clasifica dentro de las epilepsias focales idiopaticas benignas. No existe consenso sobre la indicacion de neuroimagen ante un cuadro electroclinico compatible con este trastorno. Se presentan dos casos que comenzaron con un patron electroclinico compatible con SP y en los que finalmente se detectaron alteraciones estructurales occipitales. Casos clinicos. Dos ninas de 5 y 6 anos que comenzaron con episodios compatibles electroclinicamente con SP. En ambos casos, la neuroimagen mostro lesiones estructurales (displasia cortical y xantoastrocitoma pleomorfico), por lo que finalmente el diagnostico fue de epilepsia focal sintomatica occipital, con el consiguiente cambio en el pronostico y el tratamiento. Conclusiones. En la bibliografia se describen anomalias en la resonancia magnetica craneal en un 10-20% de los casos diagnosticados de SP en los que se realiza una prueba de imagen, aunque no siempre se modifica el diagnostico de SP (lesiones coincidentes). Ambos casos ejemplifican la importancia de alcanzar un diagnostico correcto mediante un estudio detallado que ha de incluir la realizacion de neuroimagen, ya que, en algunos pacientes, se detectaran lesiones cerebrales causales, por lo que el diagnostico, el tratamiento y la evolucion seran drasticamente distintos.

Published
2020
Full Text
View/download PDF

78. Unraveling Amazon tree community assembly using Maximum Information Entropy: a quantitative analysis of tropical forest ecology

Author

Edwin Pos, Luiz de Souza Coelho, Diogenes de Andrade Lima Filho, Rafael P. Salomão, Iêda Leão Amaral, Francisca Dionízia de Almeida Matos, Carolina V. Castilho, Oliver L. Phillips, Juan Ernesto Guevara, Marcelo de Jesus Veiga Carim, Dairon Cárdenas López, William E. Magnusson, Florian Wittmann, Mariana Victória Irume, Maria Pires Martins, Daniel Sabatier, José Renan da Silva Guimarães, Jean-François Molino, Olaf S. Bánki, Maria Teresa Fernandez Piedade, Nigel C. A. Pitman, Abel Monteagudo Mendoza, José Ferreira Ramos, Joseph E. Hawes, Everton José Almeida, Luciane Ferreira Barbosa, Larissa Cavalheiro, Márcia Cléia Vilela dos Santos, Bruno Garcia Luize, Evlyn Márcia Moraes de Leão Novo, Percy Núñez Vargas, Thiago Sanna Freire Silva, Eduardo Martins Venticinque, Angelo Gilberto Manzatto, Neidiane Farias Costa Reis, John Terborgh, Katia Regina Casula, Euridice N. Honorio Coronado, Juan Carlos Montero, Beatriz S. Marimon, Ben Hur Marimon-Junior, Ted R. Feldpausch, Alvaro Duque, Chris Baraloto, Nicolás Castaño Arboleda, Julien Engel, Pascal Petronelli, Charles Eugene Zartman, Timothy J. Killeen, Rodolfo Vasquez, Bonifacio Mostacedo, Rafael L. Assis, Jochen Schöngart, Hernán Castellanos, Marcelo Brilhante de Medeiros, Marcelo Fragomeni Simon, Ana Andrade, José Luís Camargo, Layon O. Demarchi, William F. Laurance, Susan G. W. Laurance, Emanuelle de Sousa Farias, Maria Aparecida Lopes, José Leonardo Lima Magalhães, Henrique Eduardo Mendonça Nascimento, Helder Lima de Queiroz, Gerardo A. C. Aymard, Roel Brienen, Juan David Cardenas Revilla, Flávia R. C. Costa, Adriano Quaresma, Ima Célia Guimarães Vieira, Bruno Barçante Ladvocat Cintra, Pablo R. Stevenson, Yuri Oliveira Feitosa, Joost F. Duivenvoorden, Hugo F. Mogollón, Leandro Valle Ferreira, James A. Comiskey, Freddie Draper, José Julio de Toledo, Gabriel Damasco, Nállarett Dávila, Roosevelt García-Villacorta, Aline Lopes, Alberto Vicentini, Janaína Costa Noronha, Flávia Rodrigues Barbosa, Rainiellen de Sá Carpanedo, Thaise Emilio, Carolina Levis, Domingos de Jesus Rodrigues, Juliana Schietti, Priscila Souza, Alfonso Alonso, Francisco Dallmeier, Vitor H. F. Gomes, Jon Lloyd, David Neill, Daniel Praia Portela de Aguiar, Alejandro Araujo-Murakami, Luzmila Arroyo, Fernanda Antunes Carvalho, Fernanda Coelho de Souza, Dário Dantas do Amaral, Kenneth J. Feeley, Rogerio Gribel, Marcelo Petratti Pansonato, Jos Barlow, Erika Berenguer, Joice Ferreira, Paul V. A. Fine, Marcelino Carneiro Guedes, Eliana M. Jimenez, Juan Carlos Licona, Maria Cristina Peñuela Mora, Carlos A. Peres, Boris Eduardo Villa Zegarra, Carlos Cerón, Terry W. Henkel, Paul Maas, Marcos Silveira, Juliana Stropp, Raquel Thomas-Caesar, Tim R. Baker, Doug Daly, Kyle G. Dexter, John Ethan Householder, Isau Huamantupa-Chuquimaco, Toby Pennington, Marcos Ríos Paredes, Alfredo Fuentes, José Luis Marcelo Pena, Miles R. Silman, J. Sebastián Tello, Jerome Chave, Fernando Cornejo Valverde, Anthony Di Fiore, Renato Richard Hilário, Juan Fernando Phillips, Gonzalo Rivas-Torres, Tinde R. van Andel, Patricio von Hildebrand, Edelcilio Marques Barbosa, Luiz Carlos de Matos Bonates, Hilda Paulette Dávila Doza, Émile Fonty, Ricardo Zárate Gómez, Therany Gonzales, George Pepe Gallardo Gonzales, Jean-Louis Guillaumet, Bruce Hoffman, André Braga Junqueira, Yadvinder Malhi, Ires Paula de Andrade Miranda, Linder Felipe Mozombite Pinto, Adriana Prieto, Agustín Rudas, Ademir R. Ruschel, Natalino Silva, César I. A. Vela, Vincent Antoine Vos, Egleé L. Zent, Stanford Zent, Bianca Weiss Albuquerque, Angela Cano, Diego F. Correa, Janaina Barbosa Pedrosa Costa, Bernardo Monteiro Flores, Milena Holmgren, Marcelo Trindade Nascimento, Alexandre A. Oliveira, Hirma Ramirez-Angulo, Maira Rocha, Veridiana Vizoni Scudeller, Rodrigo Sierra, Milton Tirado, Maria Natalia Umaña, Geertje van der Heijden, Emilio Vilanova Torre, Corine Vriesendorp, Ophelia Wang, Kenneth R. Young, Manuel Augusto Ahuite Reategui, Cláudia Baider, Henrik Balslev, Sasha Cárdenas, Luisa Fernanda Casas, William Farfan-Rios, Cid Ferreira, Reynaldo Linares-Palomino, Casimiro Mendoza, Italo Mesones, Armando Torres-Lezama, Ligia Estela Urrego Giraldo, Daniel Villarroel, Roderick Zagt, Miguel N. Alexiades, Karina Garcia-Cabrera, Lionel Hernandez, William Milliken, Walter Palacios Cuenca, Susamar Pansini, Daniela Pauletto, Freddy Ramirez Arevalo, Adeilza Felipe Sampaio, Elvis H. Valderrama Sandoval, Luis Valenzuela Gamarra, Gerhard Boenisch, Jens Kattge, Nathan Kraft, Aurora Levesley, Karina Melgaço, Georgia Pickavance, Lourens Poorter, and Hans ter Steege

Subjects
Medicine, Science
Abstract

Abstract In a time of rapid global change, the question of what determines patterns in species abundance distribution remains a priority for understanding the complex dynamics of ecosystems. The constrained maximization of information entropy provides a framework for the understanding of such complex systems dynamics by a quantitative analysis of important constraints via predictions using least biased probability distributions. We apply it to over two thousand hectares of Amazonian tree inventories across seven forest types and thirteen functional traits, representing major global axes of plant strategies. Results show that constraints formed by regional relative abundances of genera explain eight times more of local relative abundances than constraints based on directional selection for specific functional traits, although the latter does show clear signals of environmental dependency. These results provide a quantitative insight by inference from large-scale data using cross-disciplinary methods, furthering our understanding of ecological dynamics.

Published
2023
Full Text
View/download PDF

79. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.

Author

Breccia, M, Abruzzese, E, Castagnetti, F, Bonifacio, M, Gangemi, D, Sorà, F, Iurlo, A, Luciano, L, Gozzini, A, Gentile, M, Bocchia, M, Luzi, D, Maggi, A, Sgherza, N, Isidori, A, Crugnola, M, Pregno, P, Scortechini, Ar, Capodanno, I, Pizzuti, M, Foà, R., Sorà F (ORCID:0000-0002-9607-5298), Gentile M, Pizzuti M, Foà R., Breccia, M, Abruzzese, E, Castagnetti, F, Bonifacio, M, Gangemi, D, Sorà, F, Iurlo, A, Luciano, L, Gozzini, A, Gentile, M, Bocchia, M, Luzi, D, Maggi, A, Sgherza, N, Isidori, A, Crugnola, M, Pregno, P, Scortechini, Ar, Capodanno, I, Pizzuti, M, Foà, R., Sorà F (ORCID:0000-0002-9607-5298), Gentile M, Pizzuti M, and Foà R.

Abstract

Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32-72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance. Ponatinib was started at a dose of 45 mg in 60% of patients, 30 mg in 38%, and 15 mg in 2% of patients. Overall, at a median follow-up of 12 months, 85% of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.

Published
2018

83. Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis

Author

Benedittis, C., Soverini, S., CRISTINA PAPAYANNIDIS, Rondoni, M., Colarossi, S., Dal Pero, F., Zanotti, R., Matteis, G., Mancini, M., Zazzeroni, L., Elena, C., Merante, S., Grifoni, F. I., Bonifacio, M., Perbellini, O., Specchia, G., Pagano, L., Gangemi, D., Bonadonna, P., Pieri, L., Cavo, M., Martinelli, G., and De Benedittis C, Soverini S, Papayannidis C, Rondoni M, Colarossi S, Dal Pero F, Zanotti R, De Matteis G, Mancini M, Zazzeroni L, Elena C, Merante S, Grifoni FI, Bonifacio M, Perbellini O, Specchia G, Pagano L, Gangemi D, Bonadonna P, Pieri L, Cavo M, Martinelli G

Subjects
D816V mutation, somatic autoactivating point mutation, bone marrow, KIT receptor gene, Indolent Systemic Mastocytosi, Systemic Mastocytosi, ultra-deep amplicon sequencing, Systemic Mastocytosis, Systemic Mastocytosis, KIT mutations, UDS, D816V detection, KIT mutations, UDS
Published
2015

84. Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia

Author

Stagno, F, Latagliata, R, Annunziata, M, Abruzzese, E, Castagnetti, F, Iurlo, A, Bocchia, M, Crugnola, M, Sgherza, N, Guarini, A, Sora, F, Capodanno, I, Fava, C, Gozzini, A, Bonifacio, M, Leonetti, Sc, Galimberti, S, Feo, C, Montefusco, E, Tiribelli, M, Pregno, P, Bergamaschi, M, Rizzo, M, Antolino, A, Mauro, E, Rossi, Ar, Martino, B, Palmieri, R, Esposito, Mr, Iovine, M, Danise, P, Sica, A, Vigneri, P, Breccia, M, Rosti, G, Foa, R, and Luciano, L

Published
2017

85. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

Author

Castagnetti, F, Gugliotta, G, Breccia, M, Iurlo, A, Levato, L, Albano, F, Vigneri, Paolo, Abruzzese, E, Rossi, G, Rupoli, S, Cavazzini, F, Martino, B, Orlandi, E, Pregno, P, Annunziata, M, Usala, E, Tiribelli, M, Sica, S, Bonifacio, M, Fava, C, Gherlinzoni, F, Bocchia, M, Soverini, S, Bochicchio, Mt, Cavo, M, Giovanni, M, Saglio, G, Pane, F, Baccarani, M, Rosti, G, on behalf of the GIMEMA CML Working Party, Castagnetti, Fausto, Gugliotta, Gabriele, Breccia, Massimo, Iurlo, Alessandra, Levato, Luciano, Albano, Francesco, Vigneri, Paolo, Abruzzese, Elisabetta, Rossi, Giuseppe, Rupoli, Serena, Cavazzini, Francesco, Martino, Bruno, Orlandi, Ester, Pregno, Patrizia, Annunziata, Mario, Usala, Emilio, Tiribelli, Mario, Sica, Simona, Bonifacio, Massimiliano, Fava, Carmen, Gherlinzoni, Filippo, Bocchia, Monica, Soverini, Simona, Bochicchio, Maria Teresa, Cavo, Michele, Giovanni, Martinelli, Saglio, Giuseppe, Pane, Fabrizio, Baccarani, Michele, and Rosti, Gianantonio

Subjects
Oncology, Male, Transcription, Genetic, bcr-abl, Fusion Proteins, bcr-abl, BCR-ABL1, Chronic myeloid leukemia, Philadelphia chromosome, imatinib, prognosis, transcript type, cytogenetic response, 0302 clinical medicine, CHRONIC-PHASE, CYTOGENETIC RESPONSE, MOLECULAR-BIOLOGY, END-POINTS, 800 MG, RECOMMENDATIONS, SURVIVAL, CML, BREAKPOINT, E13A2, hemic and lymphatic diseases, 80 and over, Medicine, molecular biology, Chronic, Young adult, Prospective cohort study, Aged, 80 and over, breakpoint, Leukemia, Philadelphia Chromosome Positive, Myeloid leukemia, Hematology, Middle Aged, Prognosis, Treatment Outcome, 030220 oncology & carcinogenesis, Imatinib Mesylate, Female, Transcription, prognosi, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Socio-culturale, Antineoplastic Agents, Aged, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm Grading, Neoplasm Staging, Proportional Hazards Models, Protein Kinase Inhibitors, Young Adult, survival, 03 medical and health sciences, Genetic, Internal medicine, end points, chronic phase, cytogenetic response, molecular biology, end points, recommendations, survival, CML, breakpoint, chronic phase, business.industry, Proportional hazards model, Fusion Proteins, Imatinib, medicine.disease, Settore MED/15 - MALATTIE DEL SANGUE, Immunology, recommendations, BCR-ABL Positive, business, Myelogenous, 030215 immunology
Abstract

The most frequent BCR-ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the e13a2 (b2a2) and the e14a2 (b3a2) ones. In the imatinib era few studies addressing the prognostic significance of the BCR-ABL1 transcript type in early chronic phase CML have been published. Overall, these studies suggest that in e14a2 patients the response to imatinib is faster and deeper. To evaluate if the BCR-ABL1 transcript type (e13a2 compared to e14a2) affect the response to imatinib and the clinical outcome in newly diagnosed adult CML patients, 559 patients enrolled in 3 prospective studies (NCT00514488, NCT00510926, observational study CML/023) were analyzed. A qualitative PCR was performed at baseline: 52% patients had a e14a2 transcript, 37% a e13a2 transcript, 11% co-expressed both transcripts and 1% had other rare transcripts. The median follow-up was 76 months (95% of the patients had at least a 5-year observation). The complete cytogenetic response rates were comparable in e14a2 and e13a2 patients. The median time to MR(3.0) (6 and 12 months) and MR(4.0) (41 and 61 months) was significantly shorter for e14a2 patients compared to e13a2 patients, with a higher cumulative probability of MR(3.0) (88% and 83%, p

Published
2017

86. Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms

Author

Barbui, T, De Stefano, V, Carobbio, A, Di Lazzaro, V, Guglielmelli, P, Iurlo, A, Finazzi, M, Rumi, E, Cervantes, F, Elli, E, Randi, Ml, Griesshammer, M, Palandri, F, Bonifacio, M, Hernandez, E, Cacciola, Rossella Rosaria, Cacciola, E, Palova, M, Carli, G, Beggiato, E, Martinelli, E, Musolino, C, Gaidano, G, Tieghi, A, Lunghi, F, Loscocco, G, Cattaneo, D, Cortelezzi, A, Betti, S, Rossi, E, Finazzi, G, Censori, B, Cazzola, M, Bellini, M, Arellano, V, Bertozzi, I, Sadiadian, P, Vianelli, N, and Scaffidi, L.

Published
2017

87. Metalloproteasi, Vascular Endothelial Growth Factor (VEGF), Angiopoietina 1 (ANG-1) ed Angiopoietina 2 (ANG-2) nelle lesioni endometriosiche e nell’endometrio eutopico: ruolo dell’angiogenesi nell’etiopatogenesi dell’endometriosi

Author

Bonifacio M, 5.3. ., Di Carlo, C., Guerra, G., Cirillo, D., Ambrosio, C., Nappi, C., DI SPIEZIO SARDO, ATTILIO, Bonifacio M., Di Carlo C., Guerra G., Cirillo D., Ambrosio C., Di Spiezio Sardo A., Nappi C., Bonifacio M, 5. 3. ., Di Carlo, C., Guerra, G., Cirillo, D., Ambrosio, C., DI SPIEZIO SARDO, Attilio, and Nappi, C.

Published
2005

88. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.

Author

Iurlo, A, Galimberti, S, Abruzzese, E, Annunziata, M, Bonifacio, M, Latagliata, R, Pregno, P, Ferrero, D, Sora', Federica, Orlandi, Em, Fava, Chiara, Cattaneo, Davide, Bucelli CBinotto, G, Pungolino, E, Tiribelli, M, Gozzini, A, Gugliotta, G, Castagnetti, F, Stagno, F, Rege-Cambrin, G, Martino, B, Luciano, L, Breccia, M, Sica, Simona, Bocchia, M, Pane, F, Saglio, G, Rosti, G, Specchia, G, Cortelezzi, A, Baccarani, M, Sorà F (ORCID:0000-0002-9607-5298), Sica S (ORCID:0000-0003-2426-3465), Iurlo, A, Galimberti, S, Abruzzese, E, Annunziata, M, Bonifacio, M, Latagliata, R, Pregno, P, Ferrero, D, Sora', Federica, Orlandi, Em, Fava, Chiara, Cattaneo, Davide, Bucelli CBinotto, G, Pungolino, E, Tiribelli, M, Gozzini, A, Gugliotta, G, Castagnetti, F, Stagno, F, Rege-Cambrin, G, Martino, B, Luciano, L, Breccia, M, Sica, Simona, Bocchia, M, Pane, F, Saglio, G, Rosti, G, Specchia, G, Cortelezzi, A, Baccarani, M, Sorà F (ORCID:0000-0002-9607-5298), and Sica S (ORCID:0000-0003-2426-3465)

Abstract

Pleural effusion (PE) represents the leading cause of dasatinib (DAS) discontinuation. However, the pathogenic mechanism of this adverse event (AE) is unknown and its management unclear. We investigated if a DAS dose reduction after the first PE would prevent the recurrence of this AE. We retrospectively collected data on all the cases of PE in CML-chronic phase (CP) DAS-treated patients from November 2005 to February 2017 in 21 Italian hematological centers. We identified 196 cases of PE in a series of 853 CML-CP DAS-treated patients (incidence 23.0%). DAS starting dose was 100 mg/day in 70.4% of patients, less than 100 mg/day in 14.3%, and more than 100 mg/day in the remaining cases. Median time from DAS start to PE was 16.6 months. At first PE development, 28.6% of patients were in MMR, and 37.8% in deep molecular response (DMR). DAS was temporary interrupted in 71.9% of cases, with a dose reduction in 59.2%. Recurrence was observed in 59.4% of the cases. Treatment was definitively discontinued due to PE in 29.1% of the cases. Interestingly, among patients whose DAS dosage was reduced, 59.5% experienced PE recurrence. DAS dose reduction after the first episode of PE did not prevent recurrence of this AE. Therefore, once a MMR or a DMR is achieved, different strategies of DAS dose management can be proposed prior to the development of PE, such as daily dose reduction or, as an alternative option, an on/off treatment with a weekend drug holiday.

Published
2017

89. Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells

Author

Cavalieri E, Rigo A, Bonifacio M, Carcereri de Prati A, Guardalben E, Pizzolo G, Suzuki H, Vinante F., BERGAMINI, CHRISTIAN, FATO, ROMANA, Cavalieri E, Rigo A, Bonifacio M, Carcereri de Prati A, Guardalben E, Bergamini C, Fato R, Pizzolo G, Suzuki H, and Vinante F.

Subjects
hemic and lymphatic diseases, ACUTE MYELOID-LEUKEMIA, IMATINIB-RESISTANT, ACUTE LYMPHOBLASTIC-LEUKEMIA
Abstract

BACKGROUND: We previously demonstrated that the plant-derived agent α-bisabolol enters cells via lipid rafts, binds to the pro-apoptotic Bcl-2 family protein BID, and may induce apoptosis. Here we studied the activity of α-bisabolol in acute leukemia cells. METHODS: We tested ex vivo blasts from 42 acute leukemias (14 Philadelphia-negative and 14 Philadelphia-positive B acute lymphoid leukemias, Ph-/Ph+B-ALL; 14 acute myeloid leukemias, AML) for their sensitivity to α-bisabolol in 24-hour dose-response assays. Concentrations and time were chosen based on CD34+, CD33+my and normal peripheral blood cell sensitivity to increasing α-bisabolol concentrations for up to 120 hours. RESULTS: A clustering analysis of the sensitivity over 24 hours identified three clusters. Cluster 1 (14 ± 5 μM α-bisabolol IC50) included mainly Ph-B-ALL cells. AML cells were split into cluster 2 and 3 (45 ± 7 and 65 ± 5 μM IC50). Ph+B-ALL cells were scattered, but mainly grouped into cluster 2. All leukemias, including 3 imatinib-resistant cases, were eventually responsive, but a subset of B-ALL cells was fairly sensitive to low α-bisabolol concentrations. α-bisabolol acted as a pro-apoptotic agent via a direct damage to mitochondrial integrity, which was responsible for the decrease in NADH-supported state 3 respiration and the disruption of the mitochondrial membrane potential. CONCLUSION: Our study provides the first evidence that α-bisabolol is a pro-apoptotic agent for primary human acute leukemia cells.

Published
2011

90. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Author

Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., on behalf of the GIMEMA CML Working Party (Lucarelli, G., Polimeno, G., Ladetto, M., Pini, M., Rupoli, S., Scortechini, A. R., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Specchia, G., Russo, Rossi., Rambaldi, A., Ferrari, M. L., Palandri, F., Luatti, S., Iacobucci, I., Bochicchio, M. T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Giuliani, G., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Molica, S., Lentini, M., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cuneo, A., Ciccone, M., Bosi, A., Gozzini, A., Gobbi, M., Pierri, I., Chianese, R., De Blasio, A., Ciccone, F., Capochiani, E., Pelosini, M., Musolino, C., Russo, S., Cortelezzi, A., Luppi, M., Marasca, R., Pogliani, E. M., Gambacorti-Passerini, C., Luciano, L., Izzo, B., Ferrara, F., Annunziata, M., Mettivier, V., Sessa, U., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidor, I., Di Bartolomeo, P., Di Lorenzo, R., Vallisa, D., Trabacch, I., Pizzuti, M., Zuffa, E., Salvucci, M., Ronco, F., Lelo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Sica, S., Sorà, F., Latagliata, R., De Fabritiis, P., Trawiska, M., Amadori, S., Cantonetti, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Mengarelli, A., Romano, A., Tafuri, A., Montefusc, O., Iuliano, F., Infusino, S., Dore, F., Fozza, C., Bocchia, M., Defina, M., Liberati, Am., Luzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Nicolosi, M., Gottardi, M., Calistri, E., Fanin, R., Tiribelli, M., Pizzolo, G., Bonifacio, M., Rodeghiero, F., Di Bona, E. )., Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., and on behalf of the GIMEMA CML Working Party [, Palandri F.], Pane, Fabrizio, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, Albano, F, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M, and GAMBACORTI PASSERINI, C

Subjects
DIAGNOSED CHRONIC-PHASE, Oncology, Male, Cancer Research, Time Factors, bcr-abl, Fusion Proteins, bcr-abl, Antineoplastic Agent, Hematology, Anesthesiology and Pain Medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Cumulative incidence, Young adult, Chronic, Aged, 80 and over, Leukemia, PATIENTS RECEIVING IMATINIB, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITORS, BCR-ABL1 TRANSCRIPT LEVELS, EARLY MOLECULAR RESPONSE, CML WORKING PARTY, 3-YEAR FOLLOW-UP, EUROPEAN LEUKEMIANET, 400 MG, Myeloid leukemia, Middle Aged, Prognosis, Treatment Outcome, Retreatment, Imatinib Mesylate, Female, Tyrosine kinase, Human, medicine.drug, Adult, medicine.medical_specialty, Time Factor, Adolescent, Prognosi, Protein Kinase Inhibitor, Socio-culturale, Antineoplastic Agents, Treatment results, Follow-Up Studie, Young Adult, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, Protein Kinase Inhibitors, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Fusion Proteins, Imatinib, Follow-Up Studies, Surgery, Imatinib mesylate, BCR-ABL Positive, business, Myelogenous
Abstract

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (⩽10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.

Published
2015

93. Diagnostic and operative fertiloscopy

Author

PELLICANO, MASSIMILIANO, CIRILLO, DOMENICO, NAPPI, CARMINE, CATENA U., DI IORIO P., SIMONELLI V., SORRENTINO F., STELLA N., BONIFACIO M., Pellicano, Massimiliano, Catena, U., DI IORIO, P., Simonelli, V., Sorrentino, F., Stella, N., Bonifacio, M., Cirillo, Domenico, and Nappi, Carmine

Published
2007

95. Diagnostic performance and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and quantitative PCR for detection of low-density Plasmodium falciparum infections during a controlled human malaria infection study in Equatorial Guinea

Author

Maxmillian Mpina, Thomas C. Stabler, Tobias Schindler, Jose Raso, Anna Deal, Ludmila Acuche Pupu, Elizabeth Nyakarungu, Maria del Carmen Ovono Davis, Vicente Urbano, Ali Mtoro, Ali Hamad, Maria Silvia A. Lopez, Beltran Pasialo, Marta Alene Owono Eyang, Matilde Riloha Rivas, Carlos Cortes Falla, Guillermo A. García, Juan Carlos Momo, Raul Chuquiyauri, Elizabeth Saverino, L. W. Preston Church, B. Kim lee Sim, Bonifacio Manguire, Marcel Tanner, Carl Maas, Salim Abdulla, Peter F. Billingsley, Stephen L. Hoffman, Said Jongo, Thomas L. Richie, and Claudia A. Daubenberger

Subjects
Malaria, Rapid diagnostic test, Controlled human malaria infection, Thick blood smear, Low parasite density infections, Malaria pre-exposure, Arctic medicine. Tropical medicine, RC955-962, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Progress towards malaria elimination has stagnated, partly because infections persisting at low parasite densities comprise a large reservoir contributing to ongoing malaria transmission and are difficult to detect. This study compared the performance of an ultrasensitive rapid diagnostic test (uRDT) designed to detect low density infections to a conventional RDT (cRDT), expert microscopy using Giemsa-stained thick blood smears (TBS), and quantitative polymerase chain reaction (qPCR) during a controlled human malaria infection (CHMI) study conducted in malaria exposed adults (NCT03590340). Methods Blood samples were collected from healthy Equatoguineans aged 18–35 years beginning on day 8 after CHMI with 3.2 × 103 cryopreserved, infectious Plasmodium falciparum sporozoites (PfSPZ Challenge, strain NF54) administered by direct venous inoculation. qPCR (18s ribosomal DNA), uRDT (Alere™ Malaria Ag P.f.), cRDT [Carestart Malaria Pf/PAN (PfHRP2/pLDH)], and TBS were performed daily until the volunteer became TBS positive and treatment was administered. qPCR was the reference for the presence of Plasmodium falciparum parasites. Results 279 samples were collected from 24 participants; 123 were positive by qPCR. TBS detected 24/123 (19.5% sensitivity [95% CI 13.1–27.8%]), uRDT 21/123 (17.1% sensitivity [95% CI 11.1–25.1%]), cRDT 10/123 (8.1% sensitivity [95% CI 4.2–14.8%]); all were 100% specific and did not detect any positive samples not detected by qPCR. TBS and uRDT were more sensitive than cRDT (TBS vs. cRDT p = 0.015; uRDT vs. cRDT p = 0.053), detecting parasitaemias as low as 3.7 parasites/µL (p/µL) (TBS and uRDT) compared to 5.6 p/µL (cRDT) based on TBS density measurements. TBS, uRDT and cRDT did not detect any of the 70/123 samples positive by qPCR below 5.86 p/µL, the qPCR density corresponding to 3.7 p/µL by TBS. The median prepatent periods in days (ranges) were 14.5 (10–20), 18.0 (15–28), 18.0 (15–20) and 18.0 (16–24) for qPCR, TBS, uRDT and cRDT, respectively; qPCR detected parasitaemia significantly earlier (3.5 days) than the other tests. Conclusions TBS and uRDT had similar sensitivities, both were more sensitive than cRDT, and neither matched qPCR for detecting low density parasitaemia. uRDT could be considered an alternative to TBS in selected applications, such as CHMI or field diagnosis, where qualitative, dichotomous results for malaria infection might be sufficient.

Published
2022
Full Text
View/download PDF

97. Endometriosis: Impact on fertility

Author

Nappi, C., Bifulco, G., Cirillo, P., Guida, Maurizio, Cerrota, G., Bonifacio, M., Cirillo, D., Pellicano, M., Nappi, C., Bifulco, G., Cirillo, P., Guida, M., Cerrota, G., Bonifacio, M., Cirillo, D., and Pellicano, M.

Published
2005

99. BACK TO LIFE -LIVING, TREATING, MANAGING MYELOFIBROSIS: THE BURDEN OF ILLNESS FOR PATIENTS AND THEIR FAMILIES

Author

Marini, M. G., Cappuccio, A., Abruzzese, E., Carella, A., Lunghi, M., Loiacono, I., Palumbo, G., Bonifacio, M., Cilloni, D., Iurlo, A., Andriani, A., Benevolo, G., Minoia, C., Turri, D., Elli, E. M., Falcone, A. P., Anaclerico, B., Traficante, A., Di Renzo, N., Tiribelli, M., Calistri, E., Zambello, R., Spinosa, C., Ricco, A., FRANCESCA PALANDRI, Raucci, L., Martino, B., Annunziata, M., D Alosio, M., Liberati, A. M., Caocci, G., Maffioli, M., Breccia, M., Pugliese, N., Betti, S., Giglio, G., and Reale, L.

Subjects
quality of life, myelofibrosis
Published
2014

Catalog

Books, media, physical & digital resources
See catalog results